Back to Journals » Neuropsychiatric Disease and Treatment » Therapeutic Response to Psychedelic Therapy – Who, What, Why & How?
Neuropsychiatric Disease and Treatment
ISSN: 1178-2021
- View all (4196)
- Volume 20, 2024 (90)
- Volume 19, 2023 (249)
- Volume 18, 2022 (272)
- Volume 17, 2021 (351)
- Volume 16, 2020 (325)
- Volume 15, 2019 (353)
- Volume 14, 2018 (354)
- Volume 13, 2017 (333)
- Volume 12, 2016 (367)
- Volume 11, 2015 (340)
- Volume 10, 2014 (275)
- Volume 9, 2013 (223)
- Volume 8, 2012 (74)
- Volume 7, 2011 (87)
- Volume 6, 2010 (90)
- Volume 5, 2009 (65)
- Volume 4, 2008 (128)
- Volume 3, 2007 (105)
- Volume 2, 2006 (70)
- Volume 1, 2005 (45)
Journal Articles:
- Autism, the disorder without borders and geopolitical variations (4)
- Beneath the surface: genetic factors in schizophrenia (3)
- Epileptic disorders: advances in the diagnostic and therapeutic strategies (2)
- The effectiveness of non-pharmacological interventions for people with cognitive dysfunction (1)
- Stroke and neurorestoratology (1)
- Suicide Prevention and Intervention: Recent Evidence and Future Directions (4)
- Family and Peer Facilitated/Led Interventions for Severe Mental Health Problems (2)
- Therapeutic Response to Psychedelic Therapy – Who, What, Why & How? (3)
- Current Perspectives of Chronic Stress: from Neurobiology to Treatment (3)
- Issues and Solutions in Autism Spectrum Disorders (ASD) (9)
- Cariprazine in schizophrenia (5)
- The Caregiver Perspective on Pediatric ADHD (3)
- Volume 7 - Supplement 1 (5)
- Volume 6 - Supplement 1 (6)
Therapeutic Response to Psychedelic Therapy – Who, What, Why & How?
Psilocybin and MDMA therapy are now in Phase 3 trials for Treatment Resistant Depression and Post Traumatic Stress Disorder, respectively. Meanwhile, other psychedelics are in earlier phases of development. Blinding is largely impossible in such trials, and psychological support is given as standard. A complex interplay between drug and non-drug effects is likely to mediate outcome. Identifying this interplay may allow the optimization of the process of treatment by identifying key factors of "set" and "setting", informing models of therapy and how dosing session environments are set up. This collection focuses on non-drug factors that may serve as predictors and mediators of response to treatment with psychedelic therapy, including psilocybin, MDMA and related compounds.
Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions
Modlin NL, Creed M, Sarang M, Maggio C, Rucker JJ, Williamson V
Neuropsychiatric Disease and Treatment 2024, 20:109-135
Published Date: 20 January 2024
Use of Selective Alternative Therapies for Treatment of OCD
Khan I, Jaura TA, Tukruna A, Arif A, Tebha SS, Nasir S, Mukherjee D, Masroor N, Yosufi A
Neuropsychiatric Disease and Treatment 2023, 19:721-732
Published Date: 5 April 2023
Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis
Ko K, Carter B, Cleare AJ, Rucker JJ
Neuropsychiatric Disease and Treatment 2023, 19:2105-2113
Published Date: 5 October 2023